# EDGAR Filing Document

**Accession Number:** 0001851194
**File Stem:** 0001193125-26-019460
**Filing Date:** 2026-1
**Character Count:** 23415
**Document Hash:** a8485c01d3b360a24e5e720567efd224
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-019460.hdr.sgml**: 20260122

**ACCESSION NUMBER**: 0001193125-26-019460

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260122

**DATE AS OF CHANGE**: 20260122

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ventyx Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001851194
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832996852
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40928
- **FILM NUMBER:** 26551831

**BUSINESS ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 7604076511

**MAIL ADDRESS:**
- **STREET 1:** 12790 EL CAMINO REAL, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** 

**January 21, 2026** 

## Ventyx Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40928** | **83-2996852** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**12790 El Camino Real, Suite 200** 

**San Diego, CA 92130** 

**(Address of principal executive offices, including zip code)** 

**(760) 407-6511** 

**(Registrant's telephone number, including area code)** 

**Not Applicable** 

**(Former name or former address, if changed since last report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of exchange**<br> **on which registered** |
| Common Stock, $0.0001 par value per share | VTYX | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 

***2026 Cash Bonus Award***

On January 21, 2026, the Board of Directors (the "Board") of Ventyx Biosciences, Inc. (the "Company") and its Compensation Committee approved the grant to certain Company employees, including Raju Mohan, the Company's President and Chief Executive Officer, Roy Gonzales, the Company's Senior Vice President of Finance, Matthew Moore, the Company's Chief Operating Officer and Mark Forman, the Company's Chief Medical Officer, of a cash bonus award (a "2026 Cash Bonus Award") pursuant to the terms of a letter agreement entered into between the Company and each such employee (a "2026 Cash Bonus Award Agreement").

Each 2026 Cash Bonus Award was granted in lieu of the Company's regular 2026 annual equity grants, which were not granted due to the timing of the anticipated merger (the "Merger") between the Company and Eli Lilly and Company.

Each 2026 Cash Bonus Award Agreement provides that the employee will be eligible to earn an amount in cash for each full month the employee remains in continuous service with the Company or its subsidiary (such monthly amount, the "Monthly Amount") from January 2, 2026, through the date of the closing of the Merger, provided that the closing of the Merger must occur on or prior to April 7, 2027 (the "Closing Deadline") and the employee must remain in continuous service with the Company or its subsidiary through the date of closing of the Merger. To receive a bonus under a 2026 Cash Bonus Award Agreement, the employee must execute and return to the Company a 2026 Cash Bonus Award Agreement, which contains certain acknowledgements and a release of claims against the Company. Any amounts payable with respect to a 2026 Cash Bonus Award will be payable in a single lump sum cash payment as soon as practicable following the effective time of the Merger, but no later than the second regularly scheduled payroll date thereafter. If the closing of the Merger does not occur by the Closing Deadline, then, in lieu of the 2026 Cash Bonus Award, the 2026 Cash Bonus Award Agreement provides that it will be recommended to the Board that the employee be granted an option to purchase Company common stock, subject to the employee's continued service through the applicable date of grant of such Company Option.

The Monthly Amount of the 2026 Cash Bonus Award is approximately $145,833 for Dr. Mohan, $51,042 for Mr. Gonzales, $60,375 for Mr. Moore, and $32,083 for Dr. Forman, and the maximum aggregate amount of the 2026 Cash Bonus Award (should the closing of the Merger occur on the Closing Deadline) is $2,041,667 for Dr. Mohan, $714,583 for Mr. Gonzales, $845,250 for Mr. Moore, and $449,167 for Dr. Forman.

The foregoing summary of the principal terms of the 2026 Cash Bonus Awards does not purport to be complete and is qualified in its entirety by reference to the form of 2026 Cash Bonus Award Agreement, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

------

**Item 9.01. Financial Statements and Exhibits.** 

*(d) Exhibits* 

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 10.1 | Form of 2026 Cash Bonus Award Agreement |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

***Additional Information and Where to Find It***

The Company plans to file a proxy statement (the "Proxy Statement") with the SEC in connection with the solicitation of proxies to approve the Merger and the Merger Agreement. Promptly after filing the definitive Proxy Statement with the SEC, the Company will mail the definitive Proxy Statement and a WHITE proxy card to each stockholder entitled to vote at the special meeting to consider the adoption of the Merger Agreement. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the preliminary and definitive versions of the Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the Merger at the SEC's website (http://www.sec.gov). Copies of the Company's definitive Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by the Company with the SEC in connection with the Merger will also be available, free of charge, at the Company's investor relations website (https://ir.ventyxbio.com), or by writing to Ventyx Biosciences, Inc., Attention: Investor Relations, 12790 El Camino Real, Suite 200, San Diego, CA 92130.

***Participants in the Solicitation***

Under SEC rules, the Company and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the holders of Common Stock in connection with the Merger. Information about the directors and executive officers of the Company and their ownership of the Company's Common Stock is set forth in the definitive proxy statement for the Company's 2025 Annual Meeting of Stockholders (the "2025 Proxy Statement"), which was filed with the SEC on April 23, 2025, including the sections captioned "Director Compensation," "Executive Compensation" and "Security Ownership of Certain Beneficial Owners and Management," or its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 27, 2025, and in other documents filed by the Company with the SEC. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2025 Proxy Statement, such changes have been reflected on Forms 3 or Forms 4 filed with the SEC by the Company's directors and executive officers. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the Merger when they become available.

***Cautionary Note Regarding Forward Looking Statements***

This Current Report on Form 8-K contains "forward-looking statements" that involve substantial risks and uncertainties, including statements regarding the anticipated occurrence, manner and timing of the closing of the Merger, and actions to be taken in connection with the closing of the Merger. All statements, other than statements of historical facts, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on current beliefs and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to: the possibility that the Company's holders of Common Stock may not approve the adoption of the Merger Agreement; the Company's receipt of any competing offers or acquisition proposals; a failure to (or delay in) receiving the required regulatory clearances for the Merger; a condition to closing of the Merger may not be satisfied (or waived); the ability of each party to consummate the Merger; the closing of the Merger might be delayed or not occur at all; the diversion of management time and attention from ongoing business operations and opportunities; the response of competitors to the Merger; the effect of the Merger and the public announcement of the Merger on the Company's operations and its relationships with its suppliers, business partners, management and employees, including its ability to attract and retain key personnel; the outcome of any legal proceedings that could be instituted against the parties to the Merger; the risks inherent in drug research, development and commercialization; disruption in the Company's plans and operations attributable to the Merger; changes in the Company's business during the period between announcement and closing of the Merger; the effects of the Merger (or the announcement thereof) on the price of the Common Stock; relationships with key third parties or governmental entities, regulatory changes and developments, and the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions. For further discussion of these and other risks and uncertainties, see the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the SEC and in other filings that the Company makes with the SEC in the future. There can be no assurance that the Merger will in fact be consummated. All forward-looking statements included in this Current Report on Form 8-K are based on information available to the Company as of the date hereof. The Company expressly disclaims any obligation to publicly update or revise the forward-looking statements, except as required by law.

***No Offer or Solicitation***

This Current Report on Form 8-K is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **VENTYX BIOSCIENCES, INC.** | **VENTYX BIOSCIENCES, INC.** |
|  | By: | /s/ Raju Mohan |
|  |  | Raju Mohan, Ph.D. |
|  |  | President and Chief Executive Officer |
| Date: January 22, 2026 |  |  |

---

------

**Exhibit 10.1** 

**VENTYX BIOSCIENCES, INC.** 

**Cash Bonus Letter** 

[DATE], 2026

*via email* 

Dear [NAME],

As you know, Ventyx Biosciences, Inc. (the "**Company**"), Eli Lilly and Company ("**Parent**") and certain other parties have entered into an Agreement and Plan of Merger (the "**Merger Agreement**"), pursuant to which, upon the closing of the transactions contemplated by the Merger Agreement (the "**Closing**"), the Company will be acquired by Parent (the "**Merger**" and the effective time of the Merger, the "**Effective Time**").

We are happy to inform you that, subject to your execution and delivery of this letter (the "**Letter**") to the Company, we would like to offer you the opportunity to earn a cash award in the amount of $[___], less applicable withholdings (the "**Monthly Amount**"), for each full month that you remain continuously employed with or engaged by (as applicable) the Company (or a subsidiary thereof, as applicable) following January 2, 2026 (each such full month as measured on the second calendar day of the month) through the date immediately prior to the date of Closing (such period of time, the "**Retention Period**"), subject to the terms and conditions set forth in this Letter.

At the time of Closing, you will be eligible to receive a cash bonus equal to the product of the Monthly Amount multiplied by the number of full months that you remained continuously employed or engaged (as applicable) by the Company (or a subsidiary thereof, as applicable) during the Retention Period (the "**Bonus**"), provided that (i) you remain continuously employed or engaged (as applicable) with the Company (or a subsidiary thereof, as applicable) through the date of Closing (the "**Service Requirement**"), and (ii) the Closing occurs on or prior to April 7, 2027 (the "**Closing Deadline**" and such requirement the "**Closing Deadline Requirement**"), (iii) you satisfy the Release Requirement (as described herein), and further provided that you agree to the terms and conditions of this bonus opportunity by timely executing and returning this Letter. By way of example only, if the Closing occurs on April 20, 2026, and the terms and conditions of this Letter are satisfied, including the Service Requirement, you will be eligible to receive a Bonus in an amount equal to your Monthly Amount multiplied by three. No credit will be given for any partial month of service in the Retention Period. The maximum Bonus that you will be eligible to earn, if Closing occurs on the Closing Deadline and all other conditions are met, is the Monthly Amount multiplied by 14.

Both the Service Requirement and the Closing Deadline Requirement must be satisfied for you to earn the Bonus. In the event the Bonus is earned, it will be payable in a single lump sum cash payment as soon as practicable, or otherwise as legally required, following the Effective Time and, in any event, no later than the second (2<sup>nd</sup>) regularly scheduled payroll date that follows the Effective Time.

In the event that your employment or engagement (as applicable) with the Company (or a subsidiary thereof, as applicable) terminates for any reason prior to the date immediately prior to the date of the Closing, you will not be entitled to any portion of the Bonus, and your eligibility to receive any Bonus (or any portion thereof) will be forfeited for no consideration. If the Closing does not occur by the Closing Deadline, or if the Merger Agreement is terminated prior to the Closing Deadline, you will not be entitled to any portion of the Bonus, and your eligibility to receive any portion of the Bonus will be forfeited for no consideration. If your employment terminates following the Closing, you will not be entitled to receive any additional portion of the Bonus in the form of severance or other termination pay, under this letter or under any other agreement you are party to with the Company or Company plan in which you participate.

------

If the Bonus is forfeited as a result of the termination of the Merger Agreement or because the Closing does not occur by the Closing Deadline, it will be recommended to the Company's Board of Directors (the "**Board**") that you are granted an option to purchase shares of the Company in an amount and on the terms determined by the Board (a "**Replacement Option**"), subject to your continued service to the Company (or a subsidiary if applicable) through the date of grant of the Replacement Option. The Replacement Option will vest in equal monthly installments over four years, measured from January 2, 2026 and will have a per share exercise price equal to the fair market value of an underlying share on the date of grant, as determined by the Board.

By signing below, you hereby acknowledge and agree to release, acquit and discharge the Company, Parent, and each of their respective agents, employees, officers, directors, stockholders, related companies, predecessor and/or subsidiary corporations, successors and assigns, of and from any and all claims or causes of action of any kind or nature whatsoever, known or unknown, arising from or in any way relating to the grant of any promised, committed, proposed or future stock option or other equity award in the Company, including, but not limited to any annual or promotion stock option or other equity award in respect of fiscal year 2025, fiscal year 2026, [including with respect to the stock option award in respect of [—] shares of Company common stock that the Company indicated an intent to grant to you, including in that certain correspondence sent to you by the Company, dated [DATE],] (the "**Ungranted Equity Awards**"), whether or not previously communicated to you, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, and breach of duty under applicable state corporate law (the foregoing, the "**Release Requirement**").

You hereby acknowledge and agree that you have been advised to consult with legal counsel regarding the Release Requirement. [You further acknowledge and agree that you are familiar with Section 1542 of the Civil Code of the State of California, which states: "**A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party**." You, being aware of said statute, agree to expressly waive, effective as of the date you execute this Letter, any rights you may have to that effect with respect to any Ungranted Equity Awards, as well as under any other statute or common law principles of similar effect which provides that a general release does not extend to claims that the releaser does not know or suspect to exist in the releaser's favor at the time of executing the release, which, if known by the releaser, must have materially affected the releaser's settlement with the releasee.]

It is the Company's intent that all payments and benefits provided under this Letter are intended to be exempt from, or comply with, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and any guidance promulgated thereunder (collectively, "**Section 409A**") so that none of the payments or benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities in this Letter will be interpreted in accordance with this intent. The Company reserves the right to amend this Letter as it considers necessary or advisable to avoid the imposition of any tax imposed under Section 409A or to otherwise avoid income recognition under Section 409A prior to the actual payment of any benefits. Each payment, installment, and benefit payable under this Letter is intended to constitute a separate payment for purposes of Section 409A and all Bonus payments hereunder will be paid on or before March 15 of the year following the year in which such payment, installment, and benefit was earned.

Please note that nothing in this Letter changes your status as an at-will employee of the Company. Accordingly, you remain free to resign at any time, for any reason or for no reason, and the Company remains free to conclude its employment relationship with you at any time, with or without cause, and with or without notice.

The terms and conditions of this Letter reflect the entire agreement and understanding between you and the Company as to the subject matter herein and supersede all prior or contemporaneous agreements and understandings, whether written or oral and whether formal or informal.

------

In order to be eligible for the Bonus, you must indicate your agreement with the terms and conditions of this Letter by signing and dating this Letter where indicated below and returning an executed copy to Human Resources by email at hr@ventyxbio.com no later than [DATE].

---

| |
|:---|
| Sincerely, |
| **Ventyx Biosciences, Inc.** |
| By: |
| Raju Mohan |
| Chief Executive Officer |

---

---

| |
|:---|
| Agreed to and accepted: |
| [NAME] |
| Signature: |

---

 <br> Date: